Skip to main content
UniHealth

Doctor search

Mohammed Kashani-Sabet, MD

Dermatology · San Francisco

NPI 1629026174

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
3

Offices

3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group

Looking this up.

Hospitals listed: California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kashani-Sabet’s office at (415) 600-1020 to ask if they take your plan before you enroll.

California Medical Board record

Licence G75803 · Current

Licensed to practise in California · since 1993 · expires 2028-11-30 · State University of New York at Stony Brook Health Sciences Center.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
  • California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at California Pacific Medical Center- Van Ness Campus
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.224BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.325BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.373BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.14 (0.3 to 1.97) · 2,271 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.81 to 1.28)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths192.86 (151.51 to 234.22) · 140 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.6 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths10.3 · 60 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.5 · 143 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.8 · 356 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.3 · 259 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 173 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.1 · 2,316 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.31 (0.12 to 0.49) · 6,430 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.09 to 0.47) · 7,168 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.3 (1.5 to 5.09) · 2,196 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2.47 (1.21 to 3.74) · 925 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.63 (1.37 to 3.88) · 1,954 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.13 (6.06 to 14.2) · 1,112 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.26 (4.67 to 9.85) · 1,084 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.67 (0.31 to 3.03) · 832 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.33 (0 to 0.85) · 5,406 casesNo differentJul 2022 – Jun 2024
MRSA BacteremiaInfections0.443No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.717No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 200 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22.3 · 449 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits18.2 · 187 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits8.7 · 418 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7.1 · 260 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19.2 · 293 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (3.6 to 7.6) · 157 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.2 (7.7 to 13.5) · 157 casesNo differentJan 2024 – Dec 2024
Rate of readmission for CABGUnplanned return visits11 · 33 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.2 · 66 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.5 (9.4 to 16.7) · 551 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.3) · 219 casesNo differentJan 2024 – Dec 2024

What patients said (478 patients answered, 20% of those asked)

Patient survey stars by topic at California Pacific Medical Center- Van Ness Campus
Cleanliness4
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at California Pacific Medical Center- Van Ness Campus
Room was "always" clean75%
Nurses "always" communicated well74%
Doctors "always" communicated well77%
Staff "always" explained59%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand71%
Doctors "always" listened carefully75%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand70%
Nurses "always" listened carefully71%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp

Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at California Pacific Medical Ctr-Davies Campus Hosp
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.187BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.02 (0 to 2.09) · 232 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.98 (0.56 to 1.4)No differentJul 2022 – Jun 2024
Death rate for heart failure patientsComplications and deaths10 · 72 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.1 · 106 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.4 · 257 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.8 · 721 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.26 (0.03 to 0.49) · 2,031 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.25 (0.04 to 0.45) · 2,032 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.35 (0.94 to 5.76) · 419 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.41 (0 to 3) · 211 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.84 (1.24 to 4.44) · 414 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths11.95 (2.91 to 20.98) · 218 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.61 (1.47 to 9.75) · 198 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.74 (0.22 to 3.26) · 52 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.32 (0 to 1.28) · 1,461 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.6 · 58 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.756No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22.1 · 91 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits65.3 · 84 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-26.6 · 115 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.4 · 142 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.5 · 55 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 25 casesNoneJul 2023 – Jun 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.3) · 312 casesNo differentJan 2024 – Dec 2024

What patients said (602 patients answered, 22% of those asked)

Patient survey stars by topic at California Pacific Medical Ctr-Davies Campus Hosp
Cleanliness4
Nurse communication2
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at California Pacific Medical Ctr-Davies Campus Hosp
Room was "always" clean75%
Nurses "always" communicated well73%
Doctors "always" communicated well79%
Staff "always" explained59%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand73%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand68%
Nurses "always" listened carefully71%
Nurses "always" treated them with courtesy and respect81%
"Always" quiet at night46%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms85%

Original Medicare doctor bills

$93,564

Medicare paid this office $93,564 for 500 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Short return visit (20+ min)361$33,999$74
Destruction of precancer skin growth, 1 growth193$13,188$56
New patient visit (45+ min)88$13,015$148
Return visit (30+ min)86$9,655$104
Biopsy of related skin growth, first growth66$6,949$98
See all 10 services
Every Original Medicare service billed
Short return visit (20+ min)361$33,999$74
Destruction of precancer skin growth, 1 growth193$13,188$56
New patient visit (45+ min)88$13,015$148
Return visit (30+ min)86$9,655$104
Biopsy of related skin growth, first growth66$6,949$98
Destruction of precancer skin growth, 2-14 growths164$5,909$6
Destruction of precancer skin growth, 15 or more growths29$5,765$170
New patient visit (30+ min)15$1,386$92
Destruction of skin growth, 1-14 growths12$1,337$111
Biopsy of related skin growth, each additional growth14$932$52

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions564More than 88% of doctors who do this
Skin biopsy100More than 76% of doctors who do this

Who their Medicare patients are

500 Original Medicare patients in 2024. Average age 75 · Women 42% · Also on Medicaid 3% · Health risk score 1.06. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 57% · Coronary heart disease 22% · Cancer 18% · Atrial fibrillation 17% · Diabetes 15% · Chronic kidney disease 11% · Depression 10% · COPD 7% · Heart failure 6% · Stroke 6% · Dementia 2%.

The office billed $370,385, Medicare allowed $132,229 and paid $93,564; for 1,952 services of 15 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20245001,952751.06$370,385$93,564
20234561,618751.09$338,689$92,619
20224711,543741.09$302,089$83,651
20214431,521741.17$294,304$84,385
20204451,451751.14$306,207$74,738
20195321,486741.18$356,181$87,821
20184901,206741.16$291,790$71,851
2017459847741.13$250,154$65,665
2016417818741.14$226,328$58,107
2015371613741.19$194,607$52,875
2014323464741.14$153,919$39,898
2013329600741.31$185,957$51,054

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 10 services

Original Medicare services billed in 2023
Short return visit (20+ min)292$28,153$74
Return visit (30+ min)119$14,865$111
New patient visit (45+ min)93$14,442$155
Destruction of precancer skin growth, 1 growth160$10,684$57
Biopsy of related skin growth, first growth79$9,155$103
Measurement of lymphedema extracellular fluid29$5,718$143
Destruction of precancer skin growth, 2-14 growths120$4,165$7
Destruction of precancer skin growth, 15 or more growths11$2,381$170
Biopsy of related skin growth, each additional growth22$1,519$52
New patient visit (30+ min)13$1,182$91

2022: 9 services

Original Medicare services billed in 2022
Short return visit (20+ min)316$30,397$75
Return visit (30+ min)128$14,608$103
New patient visit (45+ min)77$11,578$150
Destruction of precancer skin growth, 1 growth140$9,824$56
Biopsy of related skin growth, first growth56$6,434$101
Destruction of precancer skin growth, 2-14 growths112$4,136$7
Destruction of precancer skin growth, 15 or more growths13$2,385$159
Biopsy of related skin growth, each additional growth17$1,103$53
New patient visit (30+ min)14$1,058$76

2021: 8 services

Original Medicare services billed in 2021
Return visit (30+ min)200$24,940$107
Short return visit (20+ min)222$19,514$74
New patient visit (45+ min)77$11,881$154
Destruction of precancer skin growth, 1 growth164$10,990$57
Biopsy of related skin growth, first growth65$7,709$106
Destruction of precancer skin growth, 2-14 growths116$4,108$7
Biopsy of related skin growth, each additional growth17$1,376$53
New patient visit (30+ min)11$965$88

2020: 8 services

Original Medicare services billed in 2020
Return visit (30+ min)202$22,695$91
New patient visit (45+ min)98$14,414$147
Short return visit (20+ min)209$14,369$57
Destruction of precancer skin growth, 1 growth147$9,482$55
Biopsy of related skin growth, first growth48$5,275$100
Destruction of precancer skin growth, 2-14 growths110$3,401$6
Destruction of precancer skin growth, 15 or more growths11$1,642$149
New patient visit (30+ min)13$1,130$87

2019: 9 services

Original Medicare services billed in 2019
Return visit (30+ min)222$25,503$93
Short return visit (20+ min)290$22,591$60
New patient visit (45+ min)116$17,130$148
Destruction of precancer skin growth, 1 growth134$8,513$55
Biopsy of related skin growth, first growth67$6,815$92
Destruction of precancer skin growth, 2-14 growths95$2,005$5
Punch biopsy, first skin growth14$1,711$122
New patient visit (30+ min)16$1,332$83
Biopsy of related skin growth, each additional growth15$774$52

2018: 8 services

Original Medicare services billed in 2018
Short return visit (20+ min)300$22,362$59
Return visit (30+ min)182$19,423$87
New patient visit (45+ min)94$13,029$139
Biopsy of single growth of skin and/or tissue62$6,844$99
Destruction of precancer skin growth, 1 growth91$6,430$58
Destruction of precancer skin growth, 2-14 growths64$1,410$5
New patient visit (30+ min)11$796$72
Biopsy of each additional growth of skin and/or tissue15$546$30

2017: 8 services

Original Medicare services billed in 2017
Return visit (30+ min)176$19,311$91
Short return visit (20+ min)240$18,602$61
New patient visit (45+ min)105$14,951$142
Biopsy of single growth of skin and/or tissue56$5,855$98
Destruction of precancer skin growth, 1 growth63$4,313$60
New patient visit (30+ min)13$1,035$80
Biopsy of each additional growth of skin and/or tissue11$338$31
Destruction of precancer skin growth, 2-14 growths41$327$6

2016: 6 services

Original Medicare services billed in 2016
Return visit (30+ min)174$18,657$87
New patient visit (45+ min)110$15,649$142
Short return visit (20+ min)185$13,192$59
Destruction of precancer skin growth, 1 growth60$4,133$61
Biopsy of single growth of skin and/or tissue39$3,967$102
Destruction of precancer skin growth, 2-14 growths44$694$5

2015: 6 services

Original Medicare services billed in 2015
New patient visit (45+ min)123$17,826$145
Return visit (30+ min)149$17,055$95
Short return visit (20+ min)137$10,031$62
Biopsy of single growth of skin and/or tissue27$2,816$104
Destruction of precancer skin growth, 1 growth40$2,542$62
Destruction of precancer skin growth, 2-14 growths22$305$6

2014: 6 services

Original Medicare services billed in 2014
New patient visit (45+ min)110$15,331$139
Return visit (30+ min)109$10,084$85
Short return visit (20+ min)135$9,225$57
Destruction of precancer skin growth, 1 growth22$1,593$69
Biopsy of single growth of skin and/or tissue12$1,154$96
Destruction of precancer skin growth, 2-14 growths14$153$10

2013: 7 services

Original Medicare services billed in 2013
Return visit (30+ min)134$16,115$87
New patient visit (45+ min)99$14,365$145
Short return visit (20+ min)138$11,065$61
Destruction of precancer skin growth, 1 growth32$2,939$75
Biopsy of single growth of skin and/or tissue22$2,335$102
New patient visit (30+ min)14$1,222$87
Destruction of precancer skin growth, 2-14 growths21$190$7

Drugs they prescribed that Part D paid

$501

Pharmacies billed $501 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 25) in 2024. Too few prescriptions to compare fairly with other clinicians.

24 generic and fewer than 11 brand-name prescriptions · $501 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Triamcinolone Acetonide11$58$5

Year by year

Part D prescribing by year
202425220% (0)None$501
20234128None0%$737
202226180% (0)0%$576
202140160% (0)0%$3,323
202033180% (0)None$3,055
201938160% (0)0%$3,698
201828120% (0)None$4,367
201724140% (0)None$3,385
201641160% (0)None$10,869
201512None0% (0)None$2,154
201426None0% (0)None$1,713
20135017NoneNone$33,989

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 1 drug

Part D drugs prescribed in 2023
Triamcinolone Acetonide19$139$7

2022: 1 drug

Part D drugs prescribed in 2022
Triamcinolone Acetonide13$64$5

2019: 1 drug

Part D drugs prescribed in 2019
Clobetasol Propionate12$1,798$150

2018: 1 drug

Part D drugs prescribed in 2018
Clobetasol Propionate14$2,795$200

2016: 1 drug

Part D drugs prescribed in 2016
Clobetasol Propionate29$9,743$336

2013: 1 drug

Part D drugs prescribed in 2013
Clobetasol Propionate11$336$31

Money from drug and device companies

$70 in 2025

Industry payments by year
202522None$70
202466None$246
202311None$37
202122$1,953$2,060
202022None$40
201939None$267

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Regeneron Healthcare SolutionsLibtayo$39
1 payment
  • Meals for Libtayo · 2025-07-07 · $39
E.R. Squibb & Sons L.L.C.Opdivo$31
1 payment
  • Meals for Opdivo · 2025-02-24 · $31
See all 2 published payments
Every published payment
Regeneron Healthcare SolutionsMeals · 2025-07-07Libtayo$39
E.R. Squibb & Sons L.L.C.Meals · 2025-02-24Opdivo$31
See earlier years (2024, 2023, 2021, 2020, 2019)

2024: $246

Payments by company in 2024
Envista HoldingsTf$96
1 payment
  • Meals for Tf · 2024-05-08 · $96
Merck Sharp & DohmeKeytruda$32
1 payment
  • Meals for Keytruda · 2024-02-12 · $32
Novartis PharmaceuticalsMekinist$30
1 payment
  • Meals for Mekinist · 2024-05-06 · $30
Kyowa KirinPoteligeo$30
1 payment
  • Meals for Poteligeo · 2024-02-09 · $30
Hologic Sales and ServiceTrunode$29
1 payment
  • Meals for Trunode · 2024-07-17 · $29
Array BiopharmaBraftovi$28
1 payment
  • Meals for Braftovi · 2024-10-17 · $28

2023: $37

Payments by company in 2023
Regeneron Healthcare SolutionsLibtayo$37
1 payment
  • Meals for Libtayo · 2023-07-24 · $37

2021: $2,060

Payments by company in 2021
E.R. Squibb & Sons L.L.C.Opdivo$1,953
1 payment
  • Consulting for Opdivo · 2021-12-21 · $1,953
SeagenTukysa$107
1 payment
  • Meals for Tukysa · 2021-05-20 · $107

2020: $40

Payments by company in 2020
E.R. Squibb & Sons L.L.C.None$22
1 payment
  • Meals · 2020-01-28 · $22
Merck Sharp & DohmeKeytruda$19
1 payment
  • Meals for Keytruda · 2020-03-02 · $19

2019: $267

Payments by company in 2019
Merck Sharp & DohmeKeytruda$158
3 payments
  • Meals for Keytruda · 2019-10-24 · $120
  • Meals for Keytruda · 2019-08-19 · $19
  • Meals for Keytruda · 2019-03-04 · $19
E.R. Squibb & Sons L.L.C.None$95
5 payments
  • Meals · 2019-11-18 · $18
  • Meals · 2019-09-16 · $18
  • Meals · 2019-04-15 · $24
  • Meals · 2019-03-11 · $24
  • Meals · 2019-01-28 · $11
Ge HealthcareNone$14
1 payment
  • Meals · 2019-01-08 · $14

Professional record

NPI
1629026174
Licence
CA G75803California G75803: Current · expires 2028-11-30
Trained
State University of New York at Stony Brook, School of Medicine, 1991
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00G758030
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
2340 Clay Street, 2nd Floor, San Francisco, CA, 94115
NPI first listed
2006-05-05
NPI last updated
2010-08-10

This is when the NPI record was last certified, not a medical board exam.